Medicaid Prescription Drug Pricing and Policy
Released: 2014-11-07T00:00:00

Summary:
Medicaid is a federal-state entitlement program that pays for health care and related services on behalf of certain low-income individuals. Prescription drugs are an optional Medicaid benefit and all states cover outpatient drugs. States can create formularies, or lists of preferred drugs, but federal rules tend to result in comprehensive coverage, even for beneficiaries enrolled in Medicaid managed care plans. Pharmaceutical manufacturers that voluntarily participate in Medicaid are required to pay rebates to states on covered outpatient drugs, which help Medicaid receive manufacturers' lowest or best price. States then share the rebate they receive from pharmaceutical manufacturers with the federal government.
In determining the amount of rebate, Medicaid law distinguishes between the following two drug types: (1) single source drugs (brand-name drugs) and innovator multiple source drugs (brand-name drugs that now have generic competition); and (2) all other, non-innovator, multiple source (generic) drugs. Rebates for the first category of drugs—drugs still under patent or those once covered by patents—have two components: a basic rebate and an additional rebate. In addition to basic and additional rebates, most states negotiate supplemental rebates with drug manufacturers, by offering to encourage use of a manufacturer's product in exchange for a price concession (rebate).
States, through retail pharmacies, purchase drugs on behalf of Medicaid beneficiaries. Medicaid pharmacy reimbursement has two components: a payment to cover the cost of the pharmacy buying the drug (ingredient cost) and a payment for the pharmacist's services in filling a prescription (dispensing fee). States set reimbursement for both ingredient costs and dispensing fees.
In FY2005, Medicaid fee-for-service (FFS) drug expenditures were approximately $43.1 billion, but by FY2013 had decreased to $19.8 billion. Over the same period, Medicaid FFS drug rebate collections were at about the same level ($12.4 billion), but managed care rebate collections increased substantially to about $4.8 billion in FY2013. The decreases in Medicaid FFS drug expenditures and the increases in rebate collections were mostly offset by at least the following other factors or trends: (1) Beginning January 1, 2006, prescription drug coverage of individuals eligible for both Medicare and Medicaid (dual eligibles) was moved from Medicaid to Medicare Part D, which resulted in substantially reduced Medicaid FFS drug spending. Due to maintenance of effort requirements, state Medicaid programs continue to pay the vast majority of dual eligible drug costs, even though those expenditures are not counted as drug spending. (2) Statutory changes helped to increased rebate collections by extending rebates to Medicaid enrollees covered by managed care plans and increasing the amount of rebates owed by drug companies. (3) The loss of patent protection for a number of commonly prescribed drugs further contributed to decreasing Medicaid drug expenditures. And (4) the rapid shift in enrollment of beneficiaries to managed care plans that cover prescription drugs.
In December 2013, Sovaldi®, a new brand-name drug, was approved by the Food and Drug Administration for treatment of hepatitis virus C (HVC) infections. Sovaldi is estimated to cost $1,000 per pill, and total treatment cost estimates range from $84,000 to more than $168,000. The rebates states and the federal government receive will help reduce Medicaid's Sovaldi expenditures, but until other equivalent drugs are available to increase competition, states may have limited leverage to negotiate additional manufacturer price concessions. Medicaid rebates, however, while buffering the cost of prescription drugs, might also contribute to drug manufacturers setting increasingly higher launch prices.
The current Medicaid drug pricing and policy infrastructure was designed for FFS, and may not work as well with significant managed care enrollment. Under managed care contracts, states generally delegate some or all of drug utilization review and individual drug claim oversight to plans, including program integrity. With managed care and pharmaceutical benefit managers (PBMs) responsible for these activities, states have responsibility for ensuring plans uphold their contract obligations. States' prescription drug monitoring is tailored to FFS drug claims. It is unclear how much oversight of managed care claims states will be able to provide. If states and the federal government currently procure drugs for Medicaid beneficiaries at some of the lowest prices, will it be possible for managed care plans to further reduce costs without imposing barriers to Medicaid beneficiaries in obtaining covered drugs?

subsections: section_title: Executive Summary
paragraphs: Medicaid is a federal-state entitlement program that pays for health care and related services on behalf of certain low-income individuals. All states participate in Medicaid, but participation is not required. If states participate, then under federal Medicaid law they are required to provide health service benefits to certain individuals—mandatory eligibility groups—but states have the option of covering other groups too. Similarly, states must cover certain services for mandatory eligibility groups, but they have the option to cover fewer services for other eligibility groups. In general, Medicaid health benefits are broad for mandatory eligibility groups, but more restricted for other eligibility groups. Prescription drugs are an optional Medicaid benefit, but all states cover outpatient drugs. States may create formularies, lists of preferred drugs, but federal rules tend to result in comprehensive coverage, even for beneficiaries enrolled in Medicaid managed care plans.
Since 1990, pharmaceutical manufacturers who voluntarily agree to participate in Medicaid are required to rebate a portion of drug payments back to states. When a manufacturer participates in Medicaid, states must make most of their drugs available to Medicaid beneficiaries. States share the rebates they receive from drug manufacturers with the federal government. The drug rebates required under federal law help the state and federal Medicaid program receive manufacturers' lowest or best price . Beginning in 2010, drug manufacturers also were required to pay rebates on drugs provided to Medicaid beneficiaries enrolled in managed care. 
subsections: section_title: Medicaid Prescription Drug Reimbursement
paragraphs: For the purpose of determining rebates, Medicaid distinguishes between two drug types: (1) single source drugs (generally, those still under patent) and innovator multiple source drugs (drugs originally marketed under a patent or original new drug application but for which there now are generic equivalents); and (2) all other, non-innovator, multiple source drugs. Rebates for the first category of drugs—drugs still under patent or those once covered by patents—have two components: a basic rebate and an additional rebate. Medicaid's basic rebate for single source and innovator multiple source drugs is the larger of either the difference between a drug's quarterly average manufacturer price (AMP) and the best price for the same period, or a flat percentage (23.1%) of the drug's quarterly AMP. Drug manufacturers owe an additional rebate when their unit prices for individual products increased faster than inflation. For all other drugs, the rebate is a flat percentage (13%) of a drug's quarterly AMP. States separately negotiate additional, supplemental, rebates with drug manufacturers in exchange for listing manufacturer products on the state's preferred drug list. 
State Medicaid agencies reimburse retail pharmacies for covered outpatient prescription drugs dispensed to Medicaid beneficiaries. Medicaid FFS payments to pharmacies for outpatient prescription drugs have two components: a payment to cover the cost of the pharmacy buying the drug (the ingredient cost) and a payment for the pharmacist's professional services in filling and dispensing the prescription (the dispensing fee). States, subject to the Centers for Medicare & Medicaid Services (CMS) approval, set reimbursement amounts for both ingredient costs and dispensing fees. Dispensing fees usually are a fixed amount, intended to cover the procuring and storing drugs, consultation, and dispensing drugs. The ingredient cost component of the pharmacy payment is an approximation of a drug's market price which is intended to reimburse the pharmacy for the cost of acquiring the drug. To encourage substitution of lower-cost generic equivalent drugs for more expensive sole source drugs, federal law requires CMS to set a maximum on what it will pay for certain multiple source drug ingredients. The maximum multiple drug ingredient payments are called federal upper limits (FULs).
section_title: Drug Expenditures and Trends
paragraphs: Based on state FY2013 Medicaid financial reports, Medicaid FFS outpatient prescription drug expenditures, net of federal and state rebates, were $16.2 billion, down from $30.7 billion in FY2005 ( Figure 1 ). However, decreases in Medicaid FFS drug expenditures do not represent an overall decrease in Medicaid prescription drug expenditures, because there have been prescription drug industry trends as well as a number of statutory changes that have shifted Medicaid drug expenditures to other spending accounts. For instance, beginning January 1, 2006, prescription drug coverage of disabled and elderly Medicaid beneficiaries—those covered by both Medicare and Medicaid (dual eligibles)—was moved from Medicaid to Medicare Part D. Dual eligibles accounted for a considerable portion of Medicaid drug expenditures, and as a result, when they were moved to Medicare Part D, Medicaid drug expenditures decreased. A maintenance of effort (MOE) provision in federal Medicare law required states to continue to pay the vast majority of dual eligible drug costs. 
Another factor that contributed to the decline in FFS drug expenditures is the recent escalation in the movement of Medicaid beneficiary drug coverage from FFS to managed care contracts that include drug coverage. One indicator of the movement to managed care coverage of drugs was the growth in managed care rebates, which were required beginning in FY2010. In FY2011, states collected $932 million (national and state supplemental rebates) in managed care rebates, which increased to $4.7 billion in FY2013 ( Table 5 ). Another indicator of the migration to managed care is the change in the number of FFS drug claims, which declined by almost 25% between FY2011-FY2012 ( Table C-1 ). Decreased drug claims for five states accounted for over 90% of the decrease. The statutory changes helped to increase overall rebate collections, which had the effect of reducing net drug expenditures. States reported collecting a total of $11.7 billion in federally required FFS rebates and an additional $726 million in state FFS supplemental drug rebates, and $4.7 billion in managed care rebates for a total of $17.2 billion in FY2013 ( Table 7 and Table 6 ). Other factors that contributed to the decline in FFS drug expenditures were drug industry trends and changes in Medicaid laws applicable to prescription drugs. The drug industry patent cliff, where a number of blockbuster drugs came off patent over a few years, reduced Medicaid FFS drug costs as these drugs became available as cheaper generic products.
Selected other Medicaid FFS prescription drug data show that average FY2013 per-person Medicaid prescription drug expenditures were just over $926 ( Table 11 ), down from $1,509 in FY2005. In FY2012, Medicaid on average paid approximately $282 for single source prescription drug claims, $149 for innovator multiple source claims, and $18 for non-innovator multiple source drug claims ( Table 12 ). Medicaid's generic prescribing rate for all states varies; the national average in FY2012 was 76% ( Table D-1 ). 
section_title: Medicaid Prescription Drug Issues
paragraphs: The Patient Protection and Affordable Care Act (ACA, P.L. 111-148 ) made a number of modifications to federal Medicaid law. The CMS published a proposed rule that provided guidance on implementation of the ACA changes in February 2012. A final rule that would codify many of the new Medicaid drug requirements is pending as of the date of this report. In December 2013, Sovaldi ® a new brand name drug was approved by the Food and Drug Administration for treatment of hepatitis virus C (HVC) infections. 
Sovaldi was estimated to cost $1,000 per pill and total treatment cost estimates can range from $84,000 to more than $168,000. Through federal health programs, including Medicaid's prescription drug benefit, federal and state governments may pay the majority of HVC treatment costs. Sovaldi has raised an issue because of its high price and that many individuals with HCV infections are covered by Medicaid. For Medicaid, states and the federal government will receive rebates for Sovaldi that will help reduce the drug's cost, but until other equivalent drugs are available to increase competition, states may have limited leverage to negotiate additional manufacturer price concessions. Medicaid rebates, while buffering the cost of prescription drugs somewhat, might also contribute to drug manufacturers setting increasingly higher launch prices. 
section_title: Conclusion
paragraphs: Medicaid's drug pricing and policy have been effective in helping to control Medicaid FFS drug expenditures. Outpatient drug expenditures have decreased and Medicaid is able to buy drugs for lower prices than Medicare Part D plans, the other major federal outpatient prescription drug purchaser. Congress has been instrumental in establishing state and federal authority to ensure Medicaid receives manufacturers' lowest prescription drug prices. Congress authorized creation of Medicaid program infrastructure to manage, monitor, and enforce prescription drug pricing. However, if the pace in the movement of Medicaid enrollees to managed care that includes prescription drug benefits continues, then prescription drug oversight may be more difficult. The current Medicaid drug pricing and policy infrastructure was designed for FFS, and may not work as well with significant managed care enrollment. States have authority to collect rebates under managed care arrangements, although how state supplemental rebates will align with managed care plan drug discount negotiations is unclear. Under managed care contracts, states generally delegate some or all of drug utilization review and individual drug claim oversight to plans, including program integrity. When managed care and PBMs are responsible for these activities, states have responsibility for ensuring plans uphold their contract obligations. States' prescription drug monitoring is tailored to FFS drug claims, and it is unclear how much oversight of managed care claims states will be able to provide. If states and the federal government currently procure drugs for Medicaid beneficiaries at some of the lowest prices, will it be possible for managed care plans and PBMs to further reduce costs without imposing barriers to Medicaid beneficiaries in obtain covered drugs? 
section_title: Overview
paragraphs: Medicaid drug pricing and policy is complex, in part because prescription drug markets are dynamic. Drug manufacturers and wholesalers adapt to policy and statutory changes by creating new products and new marketing approaches that sometimes circumvent Medicaid pricing rules. Drug companies and health insurers operate in private markets in which they are seeking private advantages to earn revenue and profits. Medicaid pricing policies are, in part, based on competitive market transactions. Even though Medicaid buys drugs through the same markets as other payers, federal law requires drug companies, operating through wholesalers and distributors, to sell drugs to Medicaid at discounted prices. Medicaid's drug discounts vary depending on whether drugs are available from one manufacturer—single source—or are available from two or more manufacturers—multiple source. Single source drug discounts are greater than multiple source drug discounts. In 2010, the Congressional Budget Office (CBO) estimated that total single source Medicaid drug rebates averaged approximately 57% of manufacturers' average prices.
This report discusses how Medicaid pays for drugs, including statutory requirements on manufacturers and states as well as a number of regulations and policies that help to administer the program. Medicaid beneficiaries are dispensed drugs at retail pharmacies, but states pay most of the cost of those drugs. States then receive discounts from drug manufacturers in the form of rebate payments, which states share with the federal government through a credit against states' future Medicaid payments. Since 2006, the amount states and the federal government have spent on drugs for beneficiaries enrolled in fee-for-service (FFS) Medicaid has decreased whereas the amount states have collected from rebates has increased. 
The focus of this report is on FFS prescription drug pricing and policy. FFS drug spending accounted for the vast majority of Medicaid drug purchases in 2010, with CBO estimating that prescription drug purchases on behalf of Medicaid beneficiaries enrolled in managed care contracts represented approximately 10% of Medicaid drug expenditures. However, Medicaid managed care contracts including prescription drug coverage have grown very rapidly since FY2010. Data for Medicaid managed care drug expenditures are not as readily available as those for FFS drug spending because those expenditures are not separately reported on Medicaid financial reporting forms. Nonetheless, when possible or appropriate, information on managed care prescription drug spending and utilization is included in the discussion in this report, but in general managed care drug expenditures and utilization are outside its scope. There is considerable Medicaid and related health expenditure data present throughout this report. These data are nominal and have not been inflation adjusted. This report will be revised as new data and information become available.
A number of Medicaid drug pricing terms are commonly abbreviated. Table 1 displays many of the Medicaid drug-related acronyms and abbreviations that appear in this report. In addition, Table 2 displays a list of public laws referenced throughout the report, and Table E-1 in Appendix E is a glossary of selected Medicaid drug terms. 
section_title: Medicaid Program Basics
paragraphs: Medicaid is a federal-state entitlement program that pays for medical services on behalf of certain low-income individuals. The Centers for Medicare & Medicaid Services (CMS) administers the Medicaid program under authority delegated by the Secretary of the Department of Health and Human Services (the Secretary). Estimated FY2013 federal expenditures for Medicaid benefits and administration were approximately $262 billion; state expenditures were estimated to be an additional $192 billion, for a total program cost of approximately $454 billion.
State Medicaid programs are administered and designed by the states under broad federal guidelines. All states elect to participate in Medicaid, so they are required to provide benefits to certain low-income individuals and optionally may cover other individuals. Similarly, states must cover certain basic services, but may also cover additional services. States set their provider payment rates for medical and related services, subject to limitations and federal approval. There is considerable variation across states, with some programs being relatively limited and others more generous in terms of eligible populations, covered benefits, and service payments.
Medicaid is a means-tested program. Enrollees' income and other resources must be within program financial standards. These standards vary among states and among different population groups within a state. With some exceptions, Medicaid is available only to very low income individuals—most Medicaid enrollees have incomes below the federal poverty level (FPL). Until recently, Medicaid was primarily available only to children, adult members of families with children, pregnant women, and aged, blind, or disabled individuals. People outside those categories—such as single adults and childless couples—generally did not qualify for Medicaid regardless of their income level. ACA permitted states to expand Medicaid coverage to single adults up to age 65 provided their income did not exceed 133% of FPL and required states to cover mandatory eligibility groups up to 133% of FPL.
Historically, Medicaid eligibility groups were divided into two basic classes, the categorically needy and the medically needy. These classes differentiated between beneficiaries who were eligible for Medicaid because their income was low (categorically needy) and those who were eligible because they had high medical expenses (medically needy). Categorically needy Medicaid beneficiaries received cash-assistance payments (welfare), so their eligibility was considered welfare-related. Categorically needy beneficiaries represent the majority of Medicaid beneficiaries.
Although their income may have exceeded states' Medicaid income eligibility threshold, medically needy beneficiaries were eligible for Medicaid because a high percentage of that income was used to pay medical expenses, which left only a small amount of income for other living expenses. In 2009, 33 states covered medically needy individuals and these individuals accounted for approximately 5% of national Medicaid enrollment, and 11% of Medicaid expenditures (about $37 billion).
Over time, more categorically needy eligibility groups were added. As a result, distinctions between categorically and medically needy eligibility became less useful in identifying which groups qualified for mandatory or optional benefits. Nonetheless, the distinctions are useful when considering certain benefits. Most benefits are considered mandatory only for categorically needy individuals; that is, states must cover those benefits for the categorically needy but they are an option for medically needy individuals. Other benefits, including outpatient prescription drugs, are optional for both groups of beneficiaries. Some states provide those optional benefits only to categorically needy individuals whereas other states provide optional benefits to one or more medically needy groups as well.
section_title: Medicaid Prescription Drug Benefits
paragraphs: Coverage of outpatient prescription drugs is optional for state Medicaid programs. All states cover outpatient prescription drugs for mandatory (categorically needy) eligibility groups, but they may not cover drugs for optional groups (including medically needy) and drug coverage for expansion populations may be limited to either benchmark plan coverage or a particular set of drugs. , Most states cover outpatient drugs because these drugs are considered a lower-cost alternative to other medical care. Prescription drugs may help keep enrollees healthier and potentially prevent more serious and more costly medical interventions.
In general, Medicaid FFS and managed care outpatient drug benefits are broad, encompassing most prescription drugs and many non-prescription, over-the-counter (OTC), drugs. Medicaid prescription drug coverage is broad because Medicaid law requires states to cover most drugs offered by manufacturers that have rebate agreements in effect. In addition, federal law permits states to use formularies to direct beneficiaries to equivalent lower-cost drugs, but there also must be a process by which health care providers may request covered drugs not on the formulary if the provider determines those drugs are medically necessary. When states contract with managed care plans and drug coverage is included, the plans may use their own formularies but also must have a process by which health care providers can prescribe non-formulary drugs that they determine are medically necessary.
subsections: section_title: Fee-for-Service Coverage
paragraphs: For Medicaid beneficiaries enrolled in FFS Medicaid, federal statute allows states to establish formularies. Formularies are lists of drugs that payers prefer to have prescribed to beneficiaries, generally because these drugs cost less and are considered by experts to be as safe and effective as other drug choices. When private health care insurers or providers cover only those drugs on the list and deny payment for others, the list is referred to as a closed formulary . Medicaid formularies are seldom as restrictive as the closed formularies found in the private insurance market because of two statutory requirements. The first requirement is that states must cover any non-formulary drug (with the exception of certain drugs) that is specifically requested and approved through a prior authorization process. The second requirement is that states cover all drugs offered by manufacturers that entered into rebate agreements with the Secretary. States may use formularies to exclude drugs for which there are no significant therapeutic advantages over other drugs that are included in the formularies, as long as there is a publicly available explanation for a drug's exclusion.
Although federal law ensures Medicaid formularies are not too restrictive, it also allows states to exclude certain drugs, drug classes, or drug uses from Medicaid coverage. States may still cover excluded drugs and receive federal financial participation (FFP) for them. Medicaid-excluded drugs are not subject to the requirement that states must cover all of a manufacturer's products if the manufacturer entered into a Medicaid rebate agreement with the Secretary. Federal Medicaid law also requires states to cover three additional drugs, drug classes, or their medical uses.
section_title: Medicaid Managed Care Drug Coverage
paragraphs: Many Medicaid managed care arrangements are limited risk-based contracts that rely on primary care case management (PCCM). Under PCCM and similar limited-risk contracts, Medicaid programs pay providers a small fixed fee to manage patients' care. Further, in PCCM and other non-risk bearing managed care arrangements, prescription drug benefits generally are delivered and reimbursed as FFS Medicaid benefits. 
For Medicaid beneficiaries enrolled in managed care plans, or plans to which states pay a fixed monthly capitation payment in exchange for the provision of all or some subset of covered services, Medicaid statute permits those managed care plans an exception from the FFS drug coverage rules described above. When state Medicaid programs cover drugs or other services, such as mental health or long-term care services and supports, through managed care contracts, the services covered are considered carved in to the managed care contracts. When states do not cover drug benefits or other services, those services are considered carved out of the managed care contracts. Medicaid law allows managed care plans to develop and administer drug formularies. In practice, however, when prescription drugs are covered under capitated managed care contracts, states sometimes require managed care plans to have the same coverage and formulary limits as FFS Medicaid coverage. Only some managed care contracts include prescription drug benefits, although increasingly more include drug coverage. Since 2010, as states have moved to carve-in prescription drug coverage, more states now permit managed care plans to use their own formularies. Even if states delegate formulary decisions to managed care plans, the plans must still provide access to all Medicaid covered drugs, just as required under FFS Medicaid. Medicaid managed care plans may reimburse the retail pharmacy, similar to FFS Medicaid, or they can provide outpatient drugs directly to beneficiaries. 
As shown in Table 3 , even though the Medicaid managed care enrollment percentage was over 70% in 2011 (for any managed care) these arrangements accounted for only about 25% of Medicaid benefit expenditures, which include drug expenditures.
Similarly, 2011 Medicaid benefit expenditures for comprehensive risk-based managed care contracts accounted for about 50% of enrollment but constituted only slightly less than 24% of benefit expenditures, including drug expenditures. Table 3 also displays the Medicaid managed care enrollment increase between FY2008 and FY2011, with rising percentages going to both any managed care and comprehensive risk-based arrangements. Managed care was estimated to account for about 10% of Medicaid prescription drug expenditures in 2010, a figure that was estimated to have increased to approximately 50% in 2013.
section_title: OTC Drugs
paragraphs: Many state Medicaid programs also cover OTC drugs, those medications that can be purchased without a prescription. In 2007, all states covered some OTC drugs, although no state covered all OTC drugs and most states limited coverage or imposed coverage restrictions on OTC drugs. All states covered at least some OTC drugs in the following categories: allergy, asthma, and sinus; analgesics; cough and cold; smoking cessation; digestive products; H2 antagonists; feminine products; and topical products.
section_title: Medicaid Prescription Drug Reimbursement
paragraphs: State Medicaid agencies do not purchase drugs directly from manufacturers. Instead, they most commonly reimburse retail pharmacies for covered drugs dispensed to Medicaid beneficiaries. This section discusses FFS Medicaid pharmacy reimbursement issues. 
subsections: section_title: Medicaid FFS Payments to Pharmacies for Prescription Drugs
paragraphs: Medicaid payments to pharmacies for outpatient prescription drugs have two components: a payment for what it cost pharmacists to purchase a drug ( ingredient cost ) and a payment for pharmacists' professional services in filling and dispensing prescriptions ( dispensing fee ). States, subject to CMS approval, set separate reimbursement amounts for both ingredient costs and dispensing fees. The pharmacy payment for acquiring the drug, the ingredient cost, is either an approximation of a drug's market price or the amount the pharmacy paid to buy the drug. The dispensing fee is usually a fixed amount, intended to cover drug procurement, storage, and other costs. States set their own pharmacy payments but are subject to some federal limitations. To encourage substitution of lower-cost drugs, federal Medicaid law requires the Secretary to establish a maximum payment amount for the federal share of certain multiple source drug ingredient costs—the federal upper limit (FUL). The FUL program limits the federal share of Medicaid reimbursement for certain multiple source drugs and seeks to ensure that the federal government acts as a prudent buyer by taking advantage of lower market prices for these drugs.
Under Medicaid, there are two types of multiple source drugs, innovator multiple source and non-innovator multiple source drugs. Innovator multiple source drugs were initially brand-name drugs that have lost patent protection. Non-innovator multiple source drugs are (1) multiple source drugs that were not initially single source products, (2) multiple source drugs that were marketed as generic products, or (3) drugs that entered the market before 1962 that were never marketed as generic drugs. Brand-name drugs can be single source or innovator multiple source drugs. Generally, CMS must set an FUL amount for drugs when generic versions are available, although states must set upper limits for certain other drugs .
subsections: section_title: Multiple Source Drug Federal Upper Limits
paragraphs: Federal FUL policy requires the Secretary to establish a per drug maximum for its share of Medicaid outpatient drug payments. FULs are applied in aggregate to each state's spending for drugs subject to FUL limits rather than to individual prescription drug claims. Thus, a state may reimburse pharmacies at amounts above the FUL for certain drugs and not exceed the sum of FULs in aggregate if it also reimburses pharmacies at amounts below the FUL for other drugs. The FUL aggregate is determined by first multiplying the FUL by the number of units dispensed of each drug. Those amounts are summed for all drugs subject to FULs, and that total represents the maximum amount eligible for FFP. Drugs subject to FULs are those the FDA has rated as having three or more therapeutically and pharmaceutically equivalent products. CMS identifies drugs that are subject to FULs and then calculates the maximum payment amount for those products. 
The methodology for calculating FULs is to apply a percentage adjustment to the average manufacturer price (AMP) of the least costly therapeutic equivalent. Under an ACA provision, the FUL percentage was decreased from the Deficit Reduction Act of 2005 (DRA, P.L. 109-171 ) rate of 250% of AMP to at least 175% of AMP. Drug manufacturers are required under Medicaid law to report AMP. AMP is defined in statute as the average price paid to the manufacturer by wholesalers for drugs distributed to retail community pharmacies (RCPs). CMS has calculated and publically displayed draft FULs using the current law methodology since September 2011 but has not implemented the ACA FUL policy. Thus, current FULs were based on prices in effect in 2009. CMS announced in November 2013 that it would implement the ACA FUL policy July 1, 2014. However, CMS announced in June 2014 that it would delay implementation of the ACA FUL policy, but it did not indicate the length of the delay. 
section_title: Upper Limits for All Other Drugs
paragraphs: Federal Medicaid law also sets upper limits for other drugs a category that includes drugs for which CMS has not established a specific FUL and brand-name drugs that were certified . Drugs that are certified include drugs for which a generic alternative is available, but the beneficiary's physician has specified that a brand name is medically necessary. The FUL for other drugs is determined by the following: 
Actual acquisition cost (AAC) plus a professional dispensing fee established by the state Medicaid agency; or the pharmacies' usual and customary charges to the general public. 
States may use any method to set the other drug payment as long as, in the aggregate, state payments for these other drugs are below the levels that would be determined by applying the other drug FUL. The estimated acquisition cost (EAC) is the Medicaid agency's best estimate of the price generally paid by pharmacies and other providers to acquire the drug. CMS allows states flexibility in determining EAC, although many states rely on average wholesale price (AWP) or wholesale acquisition cost (WAC), published prices available from industry compendia. Compendia are reference books or data published by private companies based on data provided by drug manufacturers. Neither AWP nor WAC are necessarily based on actual sales transactions or defined in statute. Thus, both are subject to manufacturers' decisions on what to include or exclude. The AWP is often considered a price for wholesalers to charge retailers. 
section_title: Maximum Allowable Cost
paragraphs: Most states also often develop their own maximum allowable costs (MACs) for drug pricing. States may select the drugs, including multiple source drugs covered by FULs and other drugs, as well as set the reimbursement amount for drugs subject to MACs. MAC programs enable states to achieve additional drug savings by setting lower reimbursement amounts for more multiple source drugs than for those drugs with FUL prices and using a MAC formula that sets prices lower than FUL amounts. In June 2014, CMS identified 45 states with MACs. 
section_title: State Payment Formulas
subsections: section_title: Ingredient Costs
paragraphs: States are not required to use FULs as the basis for reimbursing pharmacies for outpatient drugs dispensed to Medicaid beneficiaries. States must only ensure that federal matching funds are not used to pay drug prices that exceed FULs; there are no other federal rules on how states set drug reimbursement, although payment methodologies are approved by CMS through the state plan amendment (SPA) process. In determining what to pay pharmacies for ingredient costs, states estimate current market prices by using one or several benchmarks to approximate pharmacies' acquisition costs. Historically, AWP was the primary drug pricing benchmark used by state Medicaid to set ingredient reimbursement. 
There has been considerable disagreement about the appropriate basis for setting Medicaid multisource drug ingredient reimbursement since statutory changes were passed in DRA. In FY2009, state Medicaid pharmacy directors issued a white paper on AWP alternatives. One of the white paper's suggestions was that CMS develop a single national pricing benchmark based on average drug ingredient acquisition costs. The state pharmacy directors' AWP alternative white paper argued that a single national benchmark would provide better estimates of pharmacy acquisition costs if it were based on actual drug purchases. This approach to drug ingredient price determination, the Medicaid pharmacy directors argued, also would provide greater accuracy and transparency in how drug prices were established. In their AWP alternative white paper, the Medicaid agencies requested that CMS coordinate, develop, and support a national pricing benchmark that could replace AWP. The Department of Health and Human Services Office of Inspector General (OIG) found that AWPs were artificially inflated, which overstated drug EACs and resulted in Medicaid overpayments.
To help states determine ingredient cost reimbursement, the Secretary is required to disclose to states and the general public via a website certain pricing data reported by manufacturers on a monthly basis. The Secretary also is required to disclose the weighted average AMP and an average retail survey price for each multiple source drug. DRA permitted the Secretary to conduct a retail price survey and disclose the survey results to states and the public. CMS initiated a National Average Drug Acquisition Cost (NADAC) survey to identify retail community pharmacy (RCP) drug acquisition costs, or the estimated prices RCPs paid to purchase all Medicaid-covered outpatient drugs. CMS began publishing draft drug acquisition cost data on its website in October 2012 and updates NADAC survey data weekly. CMS also initiated a survey of average retail consumer prices but suspended this retail survey due to funding considerations. 
State Medicaid directors issued an update on the status of state use of AAC, actual acquisition cost, in setting FFS ingredient reimbursement rates. The Medicaid directors indicated that seven states were using an ACC-based rate in 2014, although only one state was using CMS's NADAC survey data. The other states conducted their own AAC surveys. States that used an AAC-based methodology generally had increased dispensing fees to offset the potentially lower ingredient payments to pharmacies. Although many states continue to base their Medicaid drug reimbursement on published retail prices, such as AWPs less some percentage or WACs plus some percentage, more states are beginning to transition to AAC (as discussed in the Medicaid director update). Under Medicaid law, states have discretion to use different formulas or percentages to adjust published prices depending on the drug or drug category (i.e., generic versus brand, physician administered, and blood clotting factors).
section_title: Dispensing Fees
paragraphs: In addition to a drug ingredient acquisition cost payment, states also pay pharmacies a dispensing fee when they fill a FFS prescription. States determine their dispensing fees, which are limited only insofar as they must be "reasonable." Most dispensing fees generally range from around $1.00 to $3.00 per prescription, but some dispensing fees may reach $10.00 and even more depending on the state methodology and other factors. Dispensing fees may range higher in states that do not use a flat fee. Dispensing fees also often are higher for generics than for single source drugs, and fees can vary by such characteristics as urban or rural location, for profit or non-profit status, and for federally qualified health centers. Some states use tiered dispensing fees, where the rate decreases as a pharmacy's historical annual prescription volume increases. In general, states may set higher dispensing fees to help offset a pharmacy's higher costs for filling certain types of prescriptions or lower profit on reimbursement for ingredients and to encourage generic substitution, where possible. 
section_title: Medicaid Drug Rebates
paragraphs: In 1990, Congress amended the Social Security Act (SSA) to add the Medicaid Drug Rebate (MDR) program to Medicaid law. Under the MDR program, drug manufacturers that want to sell their drugs to state Medicaid agencies must enter into rebate agreements with the Secretary on behalf of states. The MDR agreements require drug manufacturers to provide state Medicaid programs with rebates on drugs purchased for Medicaid beneficiaries to ensure that Medicaid receives the lowest or best price for which the manufacturer sold the drug during the previous quarter. In exchange for receiving the best price, Medicaid programs must cover all drugs marketed by those manufacturers with certain exceptions. For instance, drugs provided in hospitals and sometimes in physicians' or dentists' offices, or similar settings are exempt from rebates. Drug manufacturers must pay rebates on prescription drugs provided to Medicaid beneficiaries who receive their care through FFS as well as managed care plans. Drug manufacturers also must pay rebates on some nonprescription, OTC items, such as aspirin, when they are dispensed to a Medicaid beneficiary and covered under the state's Medicaid plan. In 2014, CMS reported there were approximately 610 drug manufacturers participating in the Medicaid drug rebate program. In FY2013, the Medicaid (state and federal) FFS rebates—basic, inflation, and supplemental—were approximately $12.4 billion (see Table 6 ).
Medicaid rebates are shared between the states and the federal government according to state federal medical assistance percentage (FMAP). A state's FMAP determines the rate at which the federal government matches states' Medicaid expenditures. Drug manufacturers compute the drug rebate amount owed each quarter based on utilization information supplied by states. States collect manufacturers' rebates and then subtract (offset) the federal share from the federal matching funds they would receive for Medicaid medical benefits. 
For rebates purposes, federal law distinguishes between two major drug categories, single source drugs and multiple source drugs. Multiple source drugs include innovator multiple source drugs—drugs once covered by patents—and non-innovator multiple source drugs—generic drugs and all other drugs, including drugs developed before FDA approval was required and OTC drugs. In addition to the two major drug types, ACA added several additional single source and innovator multiple source drug types that are treated differently for rebates. These drug types include line extensions, clotting (blood) factors, and drugs approved by the FDA for pediatric indications. The basic and additional rebate formulas for these new ACA drug types as well as single source, innovator multiple source, and non-innovator multiple source are summarized in Table 4 .
subsections: section_title: Manufacturer Rebates for Single Source and Innovator Multiple Source Drugs
paragraphs: For single source and innovator multiple source drugs, manufacturers are required to pay state Medicaid programs a basic rebate and, when they raise a drug's price faster than inflation, an additional rebate. As shown in Table 4 , the basic rebate is determined by comparing each drug's per unit AMP to that drug's per unit best price. The basic rebate is the greater of a specified percentage of AMP or the difference between the AMP and the best price. ACA increased the specified percentage of AMP from 15.1% to 23.1%. Manufacturers owe the additional rebate when a single source or innovator multiple source drugs' per unit AMP is raised faster than the inflation rate. The per unit additional rebate is the amount a drug's quarterly reported AMP exceeds the inflation-adjusted base period AMP. If the per unit quarterly AMP does not exceed the inflation-adjusted base period AMP, then no additional rebate is owed.
To determine the total rebate, a unit rebate amount for each drug—the sum of the basic and additional rebate—is multiplied by the number of units of the drug that were purchased during the quarter, as determined by the Medicaid agency. For line extension products, any version of the original product's base AMP can be used to determine the additional rebate. As displayed in Table 4 , single source and innovator multiple source pediatric and clotting factor drugs use 17.1% as the percentage to determine the basic rebate amount, but otherwise the rebate calculation, including potential additional rebates, follows the same methodology.
Medicaid law limits manufacturers' total rebate obligation for single source and innovator multiple source drugs for each dosage form and strength to no more than the current period AMP. 
section_title: Manufacturer Rebates for Non-innovator Multiple Source Drugs
paragraphs: Basic rebates for non-innovator multiple source drugs are equal to 13% of the drug's AMP. Prices offered to other payers are not considered, nor is there an additional rebate for price increases that exceed the inflation rate. 
section_title: Supplemental Rebates and State Purchasing Pools91
paragraphs: In addition to the basic and additional FFS rebates required under federal law, most states negotiate supplemental rebate agreements (SRAs) with prescription drug manufacturers. Although almost all Medicaid SRAs have been for FFS outpatient drugs, in March 2014, three states (Florida, New Hampshire, and Oregon) had submitted SPAs to establish supplemental rebate programs for Medicaid beneficiaries enrolled in managed care plans.
States can negotiate SRAs on their own or by joining with other states to form purchasing pools. In March 2014, 45 states participated in Medicaid outpatient drug SRAs through single- or multiple-state purchasing pools. States that participate in multi-state purchasing pools are able to combine their purchasing power with that of other states to negotiate greater supplemental rebates and other price concessions from manufacturers. Some states also have established intra-state pools that negotiate drug prices for Medicaid drugs as well as for drugs dispensed through other state agencies such as employee health and local government programs. Generally, states must submit SPAs to CMS outlining their SRA arrangements. 
section_title: Managed Care Rebates
paragraphs: Prior to ACA, drug manufacturers were not required to pay rebates on drugs purchased for Medicaid beneficiaries by managed care plans. To collect rebates for managed care beneficiaries, states excluded or carved out drug benefits from capitation agreements, then provided drug benefits under FFS or contracted with other entities, such as PBM companies, to provide drug benefits. Beginning in January 2010, prescription drug manufacturers were required under ACA to pay the same rebates that were required under FFS on drugs provided to Medicaid beneficiaries enrolled in managed care plans. Since ACA became law, some states have carved in prescription drug benefits to their managed care contracts, so that drugs are covered under these contracts. Managed care rebates are paid to states and shared with the federal government following the same formulas as FFS rebates. As shown in Table 5 , Medicaid managed care rebates increased substantially since 2011.
section_title: National and State FY2013 FFS Drug Expenditures and Rebates
paragraphs:  Table 6 displays FY2013 Medicaid FFS outpatient drug expenditures and total rebates for each state and all states. In FY2013, total Medicaid FFS outpatient prescription drug expenditures, before rebates, were about $19.8 billion (federal and state shares, Table 6 ). Also in FY2013, states reported collecting approximately $12.4 billion in FFS drug rebates from drug manufacturers which includes approximately $726 million in supplemental rebates not required under federal Medicaid law ( Table 6 ) and $11.7 billion in required rebates. Net FY2013 Medicaid drug expenditures (after all rebates) were approximately $7.4 billion ( Table 7 ). 
The Table 6 data may overstate Medicaid FFS rebates. ACA increased the basic rebate percentage and extended manufacturers' additional rebate obligations to line extensions. These ACA changes were retroactive to January 1, 2010. Implementation and accounting for the ACA rebate changes may have lagged behind so that states reported rebates attributable to FY2010-FY2012 utilization in the FY2013 CMS financial reports. In addition, beginning in 2010 with the added authority for states to collect rebates on drugs purchased for full-risk Medicaid managed care beneficiaries, there may have been delays in identifying transactions that were subject to the managed care rebate.
 Table 7 displays the total amount of SRA rebates collected by states for FY1997-FY2013. In FY2013, 42 states collected a total of $726 million in supplemental FFS rebates ($403 million federal share). In FY2013, California accounted for 23% of the reported supplemental rebates (federal and state shares).
section_title: National FFS Drug Expenditure Trends
paragraphs: Some data seem to suggest that Medicaid FFS drug expenditures have decreased dramatically since FY2006, but net spending changes are attributable at least in part to policy changes that have shifted drug spending from Medicaid to Medicare, increased rebates, and shifted drug coverage from FFS to managed care plans. This section discusses recent Medicaid FFS drug expenditures and patterns.
In FY1997, states reported total FFS outpatient prescription drug expenditures, net of all rebates—federal and state shares—of about $10.2 billion, or 6.3% of total program spending. In FY2005, total FFS outpatient prescription drug expenditures, net of all rebates—federal and state shares—were $30.7 billion, accounting for about 10.2% of Medicaid benefit expenditures. By FY2013, net Medicaid FFS outpatient drug expenditures had decreased to about $16.2 billion and accounted for less than 4% of benefit expenditures. Table 8 displays a summary of Medicaid benefit and outpatient prescription drug expenditures for FY1997-FY2013.
The variation in prescription drug expenditures and year-to-year percentage changes shown in Table 8 were attributable to a number of factors. Some of these factors are trends affecting the prescription drug industry and health care markets in general, such as the expiration of prescription drug patents sometimes called the patent-cliff and increasing managed care enrollment. Other policy changes attributable to federal law may be more important than industry trends in explaining Medicaid prescription drug expenditure changes. The amendments to Medicaid drug law helped to reduce outpatient Medicaid prescription drug expenditures. Figure 1 displays the recent history of Medicaid FFS outpatient prescription drug expenditures.
There are several changes shown in Figure 1 that coincide with implementation of major legislative changes. Prior to MMA, drug expenditures were steadily increasing, rising from approximately $10.2 billion in 1997 to about $30.7 billion in 2005, even though federal and state (but particularly state) rebates also were increasing. In 2006, there was a substantial decrease (of approximately $7.6 billion) in Medicaid drug expenditures to $23.1 billion when dual eligible drug expenditures were moved to Medicare Part D.
In 2010, adjusted Medicaid drug expenditures dipped again to $19.7 billion. This change was in part attributable to the fiscal relief provided to states in the form of ARRA's temporary FMAP increase, which reduced state drug expenditures because it was applied to states' phased-down state contribution (PSC) payments. , PSC payments declined from $7.8 billion in FY2009 to $3.8 billion in FY2010. The PSC decrease shifted a portion of prescription drug costs from state and federal Medicaid matching funds to federal economic recovery funding, thus reducing federal and state Medicaid drug expenditures. Although this also increased federal funding, it shifted that funding from Medicaid to another source. Net FFS drug expenditures returned to approximately the FY2009 level in FY2011 after deducting all rebates but adding in the PSC amount that states would have paid for dual eligible drug expenditures to make comparison with earlier periods consistent.
In FY2011, the increased rebate percentages and other ACA changes were just beginning to take effect. These changes boosted federal and state rebates, but drug expenditures increased considerably to $23.1 billion from $19.7 billion in FY2010. The FY2011 increase was probably attributable to reporting delays of the ACA's rebate increases. In FY2012 and FY2013, Medicaid outpatient drug expenditures (after rebates and other adjustments) were substantially reduced, falling from about $23.1 billion in FY2011 to about $18.4 billion in FY2012 and $16.2 billion in FY2013. The FY2012 and FY2013 decreases were somewhat due to modest ACA rebate increases and the rapid movement of Medicaid beneficiaries to managed care coverage that included prescription drugs. As previously discussed, these changes did not reduce prescription drug expenditures, but shifted drug expenditures to other reports.
However, looking at state Medicaid drug utilization reports, as shown in Table 9 , estimated (unadjusted, before all rebates and PSC) total Medicaid expenditures for FFS and managed care were higher and consistent with historic drug spending patterns.
Although Medicaid drug expenditures for both managed care and FFS appear to be close to their historic levels, expenditures did decline between FY2012 and FY2013 in similar ways for both managed care and FFS drug spending. The decrease could be attributable to different data sources as well as the previously mentioned reporting lags and the patent cliff.
Additional data from Medicaid financial reports can provide insight into how Medicaid FFS drug expenditures only have changed over time (not managed care). It is possible to estimate a new FFS drug expenditure by aggregating drug expenditures and rebates and by adjusting for the Medicaid drug expenditures that were moved to Medicare Part D. The net FFS drug expenditure data can then be compared with earlier periods (before 2006) to help identify changes. As shown in Table 10 , the net FFS drug spending decrease between FY2012 and FY2013 was primarily due to decreased prescription drug expenditures, rather than increased rebate collections.
FY2012 and FY2013 FFS drug expenditures fell by 20% and 12% respectively from the previous year. The FY2012 and FY2013 decreases in Medicaid FFS drug expenditures may have been caused by several factors, including the rapid growth of Medicaid managed care enrollment that included prescription drug coverage.
In FY2012 and FY2013, total Medicaid FFS drug rebate collections also decreased. The decrease in FFS drug rebates was due to reduced FFS drug expenditures—fewer drugs purchased translates to lower rebate collections.
subsections: section_title: FFS Drug Expenditures by Eligibility Group
paragraphs: This section reviews drug expenditure patterns among the major Medicaid eligibility groups in FY2005 and FY2010 (the latest year data were available). Traditionally, the majority of Medicaid expenditures have been concentrated among the elderly and disabled eligibility groups, which account for the fewest beneficiaries. In contrast, the children and family eligibility groups typically account for more individuals and lower expenditures. The drug expenditure data by basis of eligibility (BOE) show how drug utilization patterns have changed since FY2005 with more drug spending for children and adults and less for the aged and disabled eligibility groups. These changes were probably mostly due to the movement of drug coverage for beneficiaries who were dually eligible for both Medicare and Medicaid from Medicaid to Medicare Part D, the outpatient prescription drug benefit that began January 1, 2006. Table 11 displays FFS drug use and average payments by BOE. 
As shown in Table 11 , in FY2005, about 71% of Medicaid beneficiaries who were eligible because they were elderly had drug expenditures and Medicaid paid on average about $2,943 annually for their drugs. By FY2010, about 45% of Medicaid beneficiaries who were eligible because they were elderly had prescription drug expenditures, but Medicaid paid only about $451 annually for their drugs. This dramatic decrease in the number of elderly using drugs and the amount of expenditures for those drugs is mostly attributable to the MMA change that shifted outpatient drug coverage for dual eligibles, a group that typically has high drug utilization and costs, to Medicare Part D. However, even though drug costs for dual eligibles were shifted to Medicare Part D, states continued to pay the vast majority of these costs through the phased-down state contribution. Thus, the data shown in Table 11 include dual eligibles' outpatient prescription drug costs in FY2005 but do not include these expenditures in FY2010. Table 11 also shows that children had the lowest average spending and that blind or disabled enrollees had the highest. Among blind or disabled enrollees with prescription drug spending, the average amount was about $3,793 in FY2005 but had declined to about $2,692 in FY2010. For children with prescription drug spending, the average annual amount paid for drugs was about $323 in FY2005 and $379 in FY2010.
Even though these data exclude expenditures for dual eligible and Medicaid beneficiaries enrolled in Medicaid managed care plans, they provide a glimpse of the FFS spending among different eligibility groups. Among all Medicaid beneficiaries who were dispensed drugs in FY2005, the average annual Medicaid prescription drug spending was about $1,509. By FY2010, average per beneficiary annual expenditures had declined to about $926. Again, this decrease probably was due to the following combination of factors: the movement of dual eligible drug coverage from Medicaid to Medicare Part D, other Medicaid drug pricing changes, the increased availability of a number of commonly prescribed drugs as generic rather than brand-name drugs, and other trends affecting prescription drugs.
section_title: Number and Cost of Medicaid FFS Prescriptions
paragraphs:  Table 12 displays a summary of the number of prescriptions filled for different drug types—single source, innovator, and non-innovator multiple source drugs—and the total amount states reported reimbursing providers for these drugs. The mix of drugs prescribed by state Medicaid programs affects FFS drug expenditures, with single source drugs representing a higher cost than both innovator and non-innovator multiple source drugs. As Table 12 shows, Medicaid agencies reported processing more than 323.5 million prescription claims in FY2012 and the national average Medicaid FFS payment was about $72. The national data shown in Table 12 are available for each state in Appendix A and Appendix B , which show that in FY2012 average state per prescription payment for all drug categories, before rebates, ranged from a high of about $131 in Colorado to a low of about $35 in Nevada. Table 12 shows that the FY2012 average payment for single source prescription claims was $282 and about $18 for each generic prescription.
Similar to Table 12 , Table 13 displays the number of Medicaid FFS drug claims for FY2011 and FY2012, but also shows the percentage of claims of the total that were attributable to each drug category. From FY2011 to FY2012 the percentage of claims attributable to single source products declined from about 19% to about 16% and the percentage of non-innovator multiple source prescription claims increased from about 72% to 75%. During that period (FY2011-FY2012), the overall total volume of FFS claims declined by approximately 17% from about 389 million to 324 million claims. The decline in the overall volume of FFS prescriptions is probably due to states rapidly shifting beneficiaries into managed care plans that provide prescription drug coverage under their capitated rates, rather than through carved out FFS arrangements. The increase in the percentage of claims for generic versus brand products is probably due to the patent cliff. 
Also similar to Table 12 , Table 14 displays FY2011 and FY2012 Medicaid FFS drug expenditures by drug category drug expenditures, but also shows the percentage of total annual FFS drug expenditures attributable to the different drug categories. As shown in Table 14 , national total Medicaid FFS drug expenditures, before rebates, decreased by about 18% from $28.4 billion to about $23.2 billion from FY2011 to FY2012. However, expenditures for single source Medicaid FFS drugs declined, but expenditures for multiple source non-innovator drugs increased. 
 Table 13 and Table 14 together show that single source drug expenditures represent the majority of Medicaid FFS drug expenditures, accounting for more than 60% of Medicaid FFS drug spending in both FY2011 and FY2012, even though single source drugs accounted for less than 20% of total drug claims in those years. These data are before rebates. If rebates were deducted, the differences between the percentage of expenditures for single source and multiple source drugs might be closer because single source drug rebates are considerably more than rebates for multiple source drugs. CBO estimated that Medicaid's 2010 basic and additional rebate on single source drugs averaged 57% of manufacturers' average prices. 
section_title: Policies to Control Program Drug Expenditures and Utilization
paragraphs: Medicaid law permits states to use other techniques in addition to FULs and formularies to help monitor and control overall drug expenditures and utilization. Some techniques to control drug spending involve encouraging the use of lower cost, but generically or therapeutically equivalent products, and other techniques involve establishing limits that encourage appropriate utilization. The discussion in this section is primarily applicable to the administration of Medicaid FFS drug benefits, but policies to help control drug spending are widely used by all insurers that provide prescription drug coverage, including the private sector and managed care plans under contract to state Medicaid programs.
All states use all or most of these policies in some form, although there is considerable variation in the degree to which states use these policies. For instance, all states have prior authorization, but many states only require prior authorization for certain drugs. In addition, some states allow managed care plans to establish their own prior authorization procedures and policies.
One common cost and utilization process is prior authorization and the use of preferred drug lists (PDLs). PDLs identify pharmaceutical products that have been approved in advance by a committee because they were determined to be clinically effective, but lower cost than other alternative products. Providers may readily prescribe these products to Medicaid beneficiaries. Other non-PDL drugs also are covered but may only be available when they are specifically requested and approved or authorized by the Medicaid agency. Non-PDL drugs must be prior authorized or approved. When providers want to prescribe non-PDL drugs to beneficiaries, the providers (either the physician or the pharmacist) must request permission from the state Medicaid program or the program's contractor to dispense the drug.
States may establish prior authorization programs under Medicaid for all drugs or for certain classes of drugs, as long as these programs meet the following two criteria: 
1. they must respond within 24 hours to a request for approval, and 2. they must dispense at least a 72-hour supply of a covered drug in emergency situations without prior authorization.
States also may restrict the quantity of prescription drugs available to beneficiaries. Such prescribing and dispensing limits are common. The most prevalent constraint is on the drug quantity that may be dispensed for each prescription. A number of states routinely limit the amount of certain drugs dispensed to a 30-day to 34-day supply. In addition, states also sometimes limit the number of prescriptions a beneficiary can have without special approval, particularly for single source products. In 2010, 14 states limited the total number of prescriptions (single and multiple source) per beneficiary and four states capped the monthly number of prescriptions per beneficiary. The remaining 32 states, which accounted for about 40% of Medicaid's 2010 FFS drug expenditures, did not cap the number of monthly prescriptions. 
subsections: section_title: Drug Use Review
paragraphs: All states use policies to control the use of outpatient prescription drugs, and all have programs in place to assess the quality of their pharmaceutical programs. OBRA1990 required states to establish drug use review (DUR) programs by January 1993 and provided temporary enhanced federal matching payment for DUR program start-up costs. In general, DUR programs are aimed at both improving the quality of pharmaceutical care and assisting in cost containment. Selected major DUR program design features include the following: pharmacists and physicians education in identification of fraud, abuse, gross overuse, or inappropriate or medically unnecessary care; enhanced communication between pharmacists and beneficiaries; educational outreach for pharmacists, physicians, and beneficiaries; and pharmacy counseling. 
States are required to modify their Medicaid state plans to include both prospective and retrospective drug review. Prospective review is provided to beneficiaries before drugs are dispensed, whereas retrospective review is conducted after the sale on drug claims and other data using information technology.
States also are required to establish DUR boards that include appropriate health care professionals with knowledge and expertise in outpatient prescription drug prescribing, dispensing, monitoring, DUR, education, intervention, and medical quality assurance. DUR boards must include physicians and pharmacists. States are required to submit an annual DUR report to the Secretary that includes information on DUR board activity as well as on state outpatient prescription drug utilization. CMS is required to evaluate the effectiveness of each state's DUR program. Most state DUR programs are operated by vendors, and these vendors also often overlap with state fiscal agents. Based on state DUR reports, the national average generic prescribing rate was about 74% in FY2011 and about 76% in FY2012. Table D-1 displays a summary of state generic prescribing rates for FY2011 and FY2012.
section_title: Medicaid Prescription Drug Beneficiary Cost-Sharing Requirements
paragraphs: In addition to prior authorization and utilization review, many state Medicaid programs impose beneficiary cost-sharing to help control drug use and spending. Federal Medicaid law permits states to require beneficiaries to pay out of pocket costs to encourage the most cost-effective prescription drug use. To encourage the use of lower-cost drugs, states may establish different generic versus brand-name copayments for drugs included on a PDL. For people with incomes above 150% of FPL, copayments for non-preferred drugs may be as high as 20% of what Medicaid paid for the drug's ingredients. For people with income at or below 150% of FPL, copayments are limited to nominal amounts. State Medicaid programs must specify which drugs are preferred or non-preferred. States also have the option to establish different copayments for mail-order drugs than for those sold in pharmacies.
DRA amended the SSA to permit increased Medicaid prescription drug cost-sharing for Medicaid beneficiaries. Prior to DRA, most FFS cost-sharing was limited to "nominal" copayments. DRA established two additional cost-sharing options for states. The first option allows states to establish cost-sharing that exceeds nominal amounts and to vary the cost-sharing among beneficiary classes and groups or by service types. The second option, which applies specifically to outpatient prescription drugs, allows states to require beneficiaries to pay higher copayments for state-identified non-preferred drugs and no, or reduced, copayments for preferred drugs. Table 15 displays the maximum copayments states may charge for preferred and non-preferred drugs.
The two cost-sharing options come with additional limitations. Besides the specifically exempted groups, cost-sharing cannot exceed 10% of the cost of the item or service for individuals with income between 100% of FPL and 150% of FPL and 20% of the cost of the item or service for individuals with an income over 150% of FPL. Annual aggregate cost-sharing for all Medicaid benefits cannot exceed 5% of family income. Medicaid beneficiaries can be denied services for non-payment of alternative cost-sharing. 
section_title: Other Cost-Containment Strategies
paragraphs: Some states manage drug costs through the use of PBMs. Many private insurers, including those that provide coverage to federal employees under the Federal Employees Health Benefits Program (FEHBP), contract with PBMs for drug benefits management and claims payment. PBMs enable insurers to obtain discounts for pharmaceuticals that would not otherwise be available to single insurers because the PBMs administer multiple insurers' covered populations. In addition, PBMs sometimes provide administrative services intended to improve quality and control costs, such as retail pharmacy network development, mail-order pharmacy operation, formulary development, manufacturer rebate negotiation, and prescription checks for adverse drug interactions. PBMs administer a substantial portion of private health insurance prescription drug benefits and are employed by some states to administer Medicaid drug benefits, often through managed care arrangements.
section_title: Selected Medicaid Prescription Drug Laws
paragraphs: The Medicaid rebate program was authorized by Omnibus Budget Reconciliation Act of 1990 (OBRA90, P.L. 101-508 ), then amended in 1992 by the Veterans Health Care Act of 1992 ( P.L. 102-585 ). After 1992, there were few federal statutory changes to Medicaid prescription drug pricing until 2003, when the Medicare Prescription Drug Improvement and Modernization Act of 2003 (MMA, P.L. 108-173 ) was passed. MMA was the first of five laws that reshaped Medicaid drug pricing policy. These changes had a number of goals, such as increasing the amount of rebates collected by states and the federal government and strengthening the ability of states and federal policy makers to monitor and enforce compliance. A number of recent changes were made to improve or revise earlier amendments that did not achieve the desired results. 
Prescription drug policies are complicated in part because it is hard to isolate the effects of changes in a dynamic market with many private purchasers and sellers. For Medicaid, prescription drug rebates and pricing changes are further complicated because each state has some discretion in how changes are implemented and enforced. This section provides a discussion of major legislative changes to Medicaid prescription drug pricing and rebates. Table 16 displays a summary of major laws with Medicaid drug pricing provisions.
subsections: section_title: Omnibus Budget Reconciliation Act of 1990 and the Veterans Health Care Act of 1992
paragraphs: Omnibus Budget Reconciliation Act of 1990 (OBRA90, P.L. 101-508 ) established the Medicaid drug rebate program, which assured Medicaid programs would receive the best price. OBRA90 required drug manufacturers that wanted to sell their drugs to Medicaid enrollees to enter into rebate agreements with the Secretary on behalf of the states. Under the agreements, pharmaceutical manufacturers must provide Medicaid programs with rebates on drugs purchased for Medicaid beneficiaries. Under the terms of the rebate agreements, manufacturers had to give state Medicaid agencies either their best price or a rebate.
After OBRA90 was passed, federal law enabled Medicaid agencies and the federal government to purchase prescription drugs at the lowest market price (best price). An unintended consequence was that certain public health programs, the Department of Veteran's Health Affairs (VHA), the Department of Defense (DOD), and the Public Health Service (PHS) faced sharply higher drug prices. Because Medicaid best price requirements, if pharmaceutical companies gave the DOD, VHA, and PHS providers lower prices, then drug companies would be obligated to sell those products to Medicaid at that same lowest price. Although the percentages of drug manufacturer sales to DOD, PHS programs, and VHA were small, Medicaid accounted for about 12% overall drug sales. Thus, after 1990, when the Medicaid best price provision was implemented, drug manufacturers substantially increased prices to DOD, VHA, and PHS providers.
Congress corrected the oversight by passing the Veterans Health Care Act of 1992 (VHCA, P.L. 102-585 ). VHCA amended the SSA to exclude certain sales at nominal prices from the Medicaid best price determination and the Medicaid rebate calculation.
section_title: Medicare Prescription Drug Improvement and Modernization Act of 2003
paragraphs: Medicare Prescription Drug Improvement and Modernization Act of 2003 (MMA, P.L. 108-173 ) implemented many prescription drug and other Medicare program changes, but the most far-reaching was the addition of the voluntary outpatient prescription drug benefit for Medicare beneficiaries, Part D. MMA also had an important Medicaid provision that moved outpatient drug coverage for full benefit dual eligibles from Medicaid to Medicare Part D. Although Medicare Part D assumed coverage and payment for dual eligible beneficiaries, MMA contained a maintenance-of-effort provision that required states to continue to pay the majority of dual eligibles' prescription drug costs. In addition, MMA revised the AMP definition to exclude sales to Medicare Part D drug sponsors (Part D plans) in determining AMP. 
section_title: Deficit Reduction Act of 2005
paragraphs: DRA made a number of changes to Medicaid drug policies. One of these changes was modifying the formula for setting multiple source drug FULs. DRA Section 6001 required the Secretary to use a new formula for multiple source drug FULs beginning January 1, 2007. The new FUL formula was to equal 250% of the AMP of the least costly therapeutic equivalent. AMP was defined under DRA to be the average price paid to the manufacturer by wholesalers for drugs distributed to the retail pharmacy class of trade.
Before the new DRA FUL formula could be implemented, two national pharmacy associations filed a complaint challenging the DRA's FUL proposed rule on the ground that the new FULs would generally be below community pharmacies' drug acquisition costs. The court issued a preliminary injunction in December 2007 that prohibited CMS from setting FULs for Medicaid covered generic drugs based on AMP, and from disclosing AMP data except within HHS or to the Department of Justice. The court's 2007 injunction was for an indefinite period and was in place when ACA became law on March 23, 2010, but has since been lifted. CMS lacked authority to use the pre-DRA formula, which expired September 30, 2009, for setting FULs, and CMS also was unable to use the DRA authority because it was prohibited by the Medicare Improvements for Patients and Providers Act of 2010 (MIPPA, P.L. 110-275 ). Just before the MIPPA-authority for using pre-DRA FULs expired on September 30, 2009, CMS issued FULs. The FULs in place now were set in September 2009. 
In addition, DRA made the following changes: 
reduced the required number of multiple source products rated by the FDA as therapeutic and pharmaceutically equivalent from three to two; required manufacturers to report AMP to HHS; permitted the Secretary to contract for a retail drug price survey that would allow estimation of a nationwide average consumer drug price, net of all discounts and rebates; disclosed AMP to states and the public; revised the AMP definition; and required states to collect and submit data on physician administered drugs. 
section_title: Medicare Improvements for Patients and Providers Act of 2010
paragraphs: MIPPA Section 203 required the Secretary to use the pre-DRA FUL formula for setting federal multiple source drug reimbursement through September 30, 2009. The pre-DRA FUL formula was in effect prior to December 31, 2006. Under this formula, FULs were set at 150% of published prices for the least costly therapeutic equivalent. In addition, the Secretary was prohibited from making AMP prices publicly available prior to September 30, 2009.
section_title: American Recovery and Reinvestment Act of 2009
paragraphs: American Recovery and Reinvestment Act of 2009 (ARRA, P.L. 111-5 ) Section 5001 temporarily protected states from FMAP decreases and increased federal matching rates for the recession period. ARRA defined the recession period for the FMAP increase as the period that began with the first quarter of FY2009 (October 1, 2008) and ended with the first quarter of FY2011 (December 31, 2010). During the recession period, states were held harmless from FMAP declines and all states received an across-the-board 6.2 percentage point increase. In addition, certain qualifying states received an additional unemployment-related increase. The Secretary determined that state MOE requirements under MMA for dual eligible drug expenditures were subject to the temporary FMAP increase. The ARRA temporary FMAP increase was extended for an additional two quarters (until June 30, 2011) by the Education, Jobs and Medicaid Assistance Act (EJMAA, P.L. 111-226 ). 
section_title: Patient Protection and Affordable Care Act
paragraphs: Beginning January 1, 2010, with certain exceptions, ACA Section 2501 increased the flat rebate percentage used to calculate Medicaid's basic rebate for single source and innovator multiple source outpatient prescription drugs from 15.1% to 23.1% of AMP. The basic rebate percentage for multiple-source, non-innovator, and all other drugs was increased from 11% to 13% of AMP.
ACA also required the Secretary to recover the additional funds states received from drug manufacturers from increases in the basic Medicaid rebates. The Secretary is authorized to reduce Medicaid payments to states for the additional prescription drug rebates that resulted from increases in the minimum rebate percentages—the difference between 15.1% of AMP and 23.1% of AMP for single source products and the difference between 11% and 13% for generic products. ACA requires the Secretary to estimate the additional rebate amounts to recover from states based on utilization and other data. In addition, when it is determined that the recovered amount from a state for a previous quarter under-estimated the actual rebate amount (state share) the Secretary is required to make further adjustments to recover the additional rebates from states. These state payment reductions are considered overpayments to the state and offset against states' regular Medicaid draw, similar to other overpayments. They are not subject to reconsideration. 
Moreover, ACA required drug manufacturers to pay rebates to states on drugs dispensed to Medicaid beneficiaries who received care through Medicaid managed care plans, similar to the way rebates are required under previous law for FFS beneficiaries. Medicaid capitation rates paid by states to managed care plans were to be adjusted to include these rebates. Medicaid managed care plans are subject to additional reporting requirements such as submitting data to states on the total number of units of each dose, strength, and package size by National Drug Code (NDC) for each covered outpatient drug. Medicaid managed care plans can use formularies as long as there are exception processes so that excluded drugs are available through a prior authorization process. 
With certain exceptions, ACA required that additional rebates for new formulations of single source or innovator multiple source drugs, which are referred to as line extensions . Essentially, the additional (inflation) rebates for line extensions products were to be calculated as if the product was the original product. In this way the additional (inflation) rebates is the greater of the basic rebate for new products or the AMP of the new drug multiplied by highest additional (inflation) rebate for any strength of the original product (calculated for each dose and strength of the product). However, ACA limited the total rebate liability for each dosage form and strength of an individual single source or innovator multiple source drug to no more than 100% of that drug's AMP. Other features of the drug rebate program, such as Medicaid's best price requirement, were unchanged by ACA. ACA was amended before it was enacted to clarify that the calculation of the additional rebate for new formulations of existing drugs (line extensions) applied to single source or innovator multiple source drugs only in oral solid dosage forms.
ACA Section 2502 required that smoking cessation drugs, barbiturates, and benzodiazepines be removed from Medicaid's excluded drug list. When this provision took effect beginning January 1, 2014, states that covered prescription drugs were required to cover barbiturates, benzodiazepines, and smoking cessation products for most Medicaid beneficiaries.
ACA Section 2503 amended Medicaid law to require the Secretary to establish multiple source drug FULs at 175% or more of the weighted average (determined on the basis of utilization) of the most recently reported monthly AMPs. ACA restored the pre-DRA definition of multiple source drugs as at least three therapeutic and pharmaceutically equivalent products. ACA also included technical changes to the FUL formula, such as a smoothing process to reduce short-term volatility, and clarified that AMP excludes the following:
customary prompt pay discounts to wholesalers; bona fide service fees paid by manufacturers to wholesalers and RCPs, such as distribution service fees, inventory management fees, product stocking allowances, and administrative services agreements and patient care programs (medication compliance and patient education programs); reimbursement by manufacturers for recalled, damaged, expired, or unsaleable returned goods; and payments received from, and rebates or discounts to, large purchasers such as PBMs, managed care plans, health maintenance organizations, insurers, hospitals, clinics, mail-order pharmacies, long-term care providers, manufacturers, or any other entity that does not conduct business as a wholesaler or a RCP. 
ACA Section 2503 modified the AMP definition further by replacing the retail class of trade terminology with RCPs. This change excluded from drug manufacturers' AMP calculation sales to many non-traditional retail outlets, such as mail order, nursing homes, LTC pharmacies, and PBMs. Excluding drug sales through these outlets from the AMP calculation had the effect of raising AMP, thus increasing Medicaid rebates. Moreover, ACA revised the definition of a multiple source drug from one marketed in a state during the rebate period to a product marketed or sold during the rebate period in the United States. ACA expanded drug pricing disclosure requirements to include monthly weighted average AMPs and retail survey prices. Manufacturers are required to report within 30 days of the end of each month of a rebate period the total number of units sold and used by the manufacturer to calculate the AMP for each covered outpatient drug. 
section_title: Education, Jobs, and Medicaid Assistance Act
paragraphs: EJMAA Section 202 amended ACA to include in AMP sales of 5i drugs that generally are not dispensed through retail community pharmacies. This amendment was a technical change to ACA that was made to ensure that AMPs could be calculated and Medicaid rebates could be collected from manufacturers for the 5i drugs even though these products are not typically sold by RCPs. 
section_title: Selected Medicaid Prescription Drug Issues
paragraphs: This section discusses the following two Medicaid prescription drug issues: (1) new drug prices and (2) the pending final rule implementing ACA changes.
subsections: section_title: New Drug Prices
paragraphs: The rising cost of new drugs has been an issue in the past and recently has re-emerged with many groups discussing why drug prices are so high and what can be done to control new drug prices. After a period of relatively few new drugs coming to market, drug manufacturers' pipelines are filling and there could be a surge in new drugs coming to market. Many of the new drugs will be biologic products and some or many of these products will be costly. As a result, concern about rising drugs prices might only be beginning. This section briefly discusses the process for setting new drug prices and then discusses Sovaldi, a new drug launched in 2014, and how Medicaid drug pricing will affect Sovaldi and possibly other new drugs.
When drug manufacturers launch new single source drug products, they determine a product's price and generally are not subject to statutory or regulatory limits in setting drug prices. In 2013, FDA approved 27 new molecular entities; in 2012, it approved 39. A number of these newly introduced drugs are expensive, and potentially many more are anticipated. And higher initial prices do not preclude manufacturers from raising prices further after the drugs are launched. 
Many organizations, patient groups, Members of Congress, insurers, and individuals are concerned about prescription drug costs. Even going back to the 1990s, when costly antiviral drugs were introduced to treat human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS), there was considerable concern in Medicaid programs about states' ability to pay for these new drugs. In 2009, GAO published a report that found that drug manufacturers substantially increased prices for certain brand-name drugs from 2000 to 2008. GAO attributed the extraordinary price increases to a number of factors, including lack of good therapeutic alternatives, industry consolidation, and unusual events such as key ingredient supply and manufacturing disruptions. Recently, the topic of excessive new drug costs reemerged accompanying the launch of a new, more effective drug for treating hepatitis C virus (HCV), a liver infection. Pharmaceutical manufacturer Gilead Sciences, Inc. (Gilead) received FDA approval to market Sofobuvir under the brand-name Sovaldi in December 2013 for the treatment of chronic HCV infection. Sovaldi's reported list price is approximately $84,000 for a standard 12-week treatment. Patients can require up to 24 weeks of treatment, and it is usually taken in combination with other drugs, pushing the price above $160,000. In October 2014, the FDA approved a second Gilead drug for treating HCV infections, Ledipasvir/Sofosbuvir, marketed under the brand-name Harvoni ® . Gilead set Harvoni's price at approximately $1,125 per pill, which would result in a cost of about $95,000 for a 12-week treatment course.
Gilead's new HCV drugs, Sovaldi and Harvoni, are unquestionably expensive, but other. 
However, the Sovaldi product launch may differ from the launch of other drugs for the following reasons: shortage of good therapeutic alternatives, increased awareness of HCV prevalence, improved screening, and, in anticipation of Sovaldi's launch, a backlog of HCV positive individuals who needed treatment. Because many other new drugs, such as cancer drugs, replace an existing product, new cases are diagnosed gradually and a backlog of cases is unusual. With Sovaldi, many cases were already diagnosed, so there may have been considerable pent-up treatment demand. This surge for HCV treatment put added financial pressure on all payers but proved particularly heavy for Medicaid and Medicare, which cover many HCV positive individuals and differ from the more gradual financial effect of other expensive drugs that recently have come to market. 
In addition, the timing of Sovaldi's FDA approval and introduction might have contributed to the financial hardship Sovaldi is creating for Medicaid. Sovaldi was approved by the FDA in early December 2013. Because Sovaldi was approved as a breakthrough drug it received fast-track review, which shortened the review time and left less time for payers to become aware of the drug and make contract adjustments or otherwise plan for increased costs. Although December is within the federal fiscal year's first quarter, it is very late in the planning cycle for most health insurance contracts, which follow a calendar year. Medicaid managed care plans, Medicare Part D drug plans, and Medicare Part C plans may have been caught off guard by Sovaldi's early December launch. Moreover, state budgets that would provide state Medicaid matching funds for drugs purchased for Medicaid FFS beneficiaries were well past the budget planning cycle for the current state fiscal year. Medicaid programs cover Sovaldi, and as an entitlement the program would need to find fiscal resources whether or not the state had considered the cost when preparing the state's Medicaid budget estimate. 
Public health care programs, particularly Medicaid, might be more vulnerable to high prices for new drugs than private payers because cost-sharing generally is nominal and coverage is broad, but all payers experience additional costs. Members of Congress have raised concerns about the effect of these new drug treatments on federal and state budgets and the process drug makers use in setting new drug prices. Medicaid and other private organizations have raised similar concerns about Sovaldi's cost to both federal and state governments. In addition to concerns about Sovaldi, private insurers and professional associations have noted the financial impact of high drug prices in general. 
subsections: section_title: Medicaid Rebates for Sovaldi
paragraphs: Gilead participates in the Medicaid rebate program, so Sovaldi is a covered drug. Similar to established single source drugs, Medicaid agencies that purchase Sovaldi for covered FFS beneficiaries will receive the basic Medicaid rebate for their drug purchases, which is the greater of the drug's best price minus AMP or 23.1% of the product's AMP. The rebate is split between the federal government and states based on the FMAP rate for part of the rebate, and the remainder goes the federal government. As a new product, Gilead will report Sovaldi's base-period AMP on the basis of sales from the first full calendar quarter after the launch date. Also, Gilead will not owe additional Medicaid (inflation) rebates because Sovaldi is new and will not have had price increases greater than inflation until at least after the base-period AMP is established. If, or when, Sovaldi's price increases faster than its base-period AMP adjusted for inflation, then Gilead will owe an additional rebate. The additional rebate also is shared by federal and state governments. When Sovaldi is provided to Medicaid beneficiaries by managed care plans, Gilead would be obligated to pay the basic rebate for those purchases, and the additional Medicaid rebate would be applicable if or when Gilead raised prices faster the inflation adjusted base-period AMP. 
In the short term, Medicaid rebates will help to offset some of the initial cost of treating HCV-positive Medicaid beneficiaries, but Medicaid programs anticipate substantial budget effects. In the longer-term, Medicaid's cost for Sovaldi may decrease through competition from other new therapeutically equivalent products. Other drug makers have new drugs in late-stage development that have shown promise in treating HCV. If some of these other new drugs are approved, Medicaid programs will be able to negotiate with all drug manufacturers that offer HCV products to get better deals on HCV drugs. In FFS Medicaid, when competing products come to market state programs may be able to negotiate SRAs for therapeutically comparable products by offering to list one company's drug on the state PDL, essentially guaranteeing that company most sales for HVC drugs. Medicaid managed care plans also may be able to negotiate discounts when competing products come to market, either individually or through PBMs. In addition, in some situations, individual and combined multi-state purchasing pools can further increase states' leverage in negotiating additional manufacturer price concessions. Once competition is available, even though other manufacturers may price their drugs comparably to Sovaldi, Medicaid programs will be able to use PDLs and other techniques to help reduce their Sovaldi expenditures. Even before competition from other products is available, states may limit access to Sovaldi by requiring that it be used only in limited situations, such as when a beneficiary is free from drug use or when they have advanced disease. 
section_title: Hypothetical New Drug Pricing Scenario
paragraphs: Gilead's process for determining the launch price for Sovaldi is not public information. In setting prices, drug manufacturers may consider the costs their new products would offset. Would a chemotherapy drug extend a patient's life a few months or potentially cure the cancer? Would the drug diminish the likelihood of the need for surgery or, in Sovaldi's case, the need for liver transplants in some cases? If the need for liver transplants were significantly reduced, an expensive, even very expensive, drug might save the health system considerable money. Some drug industry executives attribute high drug prices to how the health care industry pays for services and supplies rather than to drug companies attempting to maximize revenue and profit.
Medicaid's drug pricing policies might also contribute to new drug price escalation, particularly for a drug such as Sovaldi that potentially will treat many Medicaid beneficiaries. Medicaid's two-tiered rebate, with a basic rebate and an additional inflation rebate, might indirectly encourage manufacturers to set higher launch prices to offset or recover the cost of Medicaid rebates by reducing the Medicaid inflation rebate. For a drug like Sovaldi, for which there is little therapeutic competition and there may be some or considerable pent up demand, a high launch price that builds in some future period price increases might reduce a manufacturer's additional rebate obligations. At launch, the manufacturer has the market to itself. If it did not raise prices, or raised prices modestly, the manufacturer would avoid most or all of Medicaid's additional inflation rebate. As the backlog of cases decreased and other new drugs came to market, competition would increase and Sovaldi might have to make price concessions to maintain its market position. At that point, Gilead might begin to raise prices much faster, which would provide negotiation room for making price concessions to states through supplemental rebates without reducing profit margins. If the drug manufacturer had not raised Sovaldi's price much while it did not have competition, when new substitute drugs came to market Gilead would have built up some room in its price for Sovaldi for inflation adjustments that it could use before triggering the inflation rebate. Whether or not drug makers are concerned about recovering Medicaid's inflation rebate or some of all Medicaid rebates is unclear, but a high launch price when there are few competing products may carry few risks for drug manufacturers.
section_title: ACA Implementation: Pending Final Rule
paragraphs: CMS published an extensive Medicaid drug rebate (MDR) program proposed rule in February 2012 that offered regulatory guidance on the implementation of ACA's Medicaid prescription drug changes. A final rule is pending but anticipated in 2015. Overall, the proposed rule offers substantial guidance to manufacturers and Medicaid programs on how CMS planned to interpret ACA's statutory changes. CMS sought industry comment on a number of issues, so it is unclear how closely a final rule will follow the proposed rule's guidance. The rule proposed modifying the Code of Federal Regulations sections to implement the Medicaid drug changes required in ACA Sections 2501, 2503, 3301, 1101, and 1206. Table 17 identifies regulations that CMS proposed to modify or create in implementing the ACA changes. 
In the proposed rule, CMS requested comments from industry on a number of issues. CMS proposed to clarify its existing guidance on a number of issues, such as the definitions section. Many of the proposed changes were intended to clarify existing rules to enhance consistency among drug manufacturers and Medicaid programs. Other proposed changes sought to more closely align CMS's policy with existing FDA drug guidance. CMS also proposed substantial changes to AMP and best price that were aimed at assisting manufacturers in computing and reporting these prices consistently. Although the proposed rule changes were extensive, only the following three new sections were added to the CFR subpart: Identification of 5i Drugs (42 CFR §§447.504(d) and 447.507), Medicaid Drug Rebate (42 CFR §447.509), and Requirements for States (42 CFR §447.511). A potential major change would be the inclusion of territories as states, which would require territory Medicaid programs to comply with all the state MDR program requirements. CMS estimated that states and the federal government would save $17.7 billion over five years from implementation of the proposed changes ($13.7 billion to the federal government and $4 billion to the states). CMS also estimated that drug manufacturers, states, and managed care plans would incur about $81.4 million in costs over the period FY2010-FY2012 in implementing the changes.
section_title: Conclusion
paragraphs: In general, FFS rebates have been effective in helping to control Medicaid FFS drug expenditures. Overall, FFS outpatient drug expenditures have decreased and Medicaid is able to buy drugs for lower prices than Medicare Part D plans and most other federal programs. Congress has been instrumental in establishing Medicaid drug authority to ensure Medicaid pays some of the lowest prescription drug prices. Congress authorized creation of the infrastructure to manage, monitor, and enforce prescription drug pricing. Congress also extended authority for Medicaid to receive rebates on drugs provided to beneficiaries in managed care, and this has resulted in the rapid movement of prescription drug coverage from FFS Medicaid to Medicaid managed care. The percentage of FFS prescription drug claims has fallen from approximately 10% in 2010 to less than 50% in 2013.
The movement of prescription drug coverage from FFS to managed care plans could make oversight of the Medicaid prescription drug benefit more difficult. States will be able to collect rebates under managed care contracts, although it is unclear how state supplemental rebates will align with managed care plan (or, more likely, PBM) negotiations with drug wholesalers and manufacturers. Under managed care contracts, states generally delegate some or all DUR and program integrity oversight to managed care plans. Will states be able to conduct DUR and appropriate monitoring comparable to FFS drug benefits? If states and the federal government already procure drugs at some of the best prices, will it be possible for managed care plans and their subcontractor PBMs to reduce costs further? Or will savings come from creating obstacles to beneficiaries receiving covered drugs through utilization controls?
Appendix A. FY2012 State FFS Drug Claims
Appendix B. FY2012 FFS Drug Paymemt
Appendix C. Medicaid FFS Prescription Drug Claims
Appendix D. State Generic Prescribing Rates
Appendix E. Glossary: Medicaid Drug Terms